{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:26:58Z","timestamp":1792985218101,"version":"4.5.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.autrev.2018.03.012","type":"journal-article","created":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T20:58:31Z","timestamp":1531256311000},"page":"882-889","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["Therapy of scleroderma renal crisis: State of the art"],"prefix":"10.1016","volume":"17","author":[{"given":"Elisabetta","family":"Zanatta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Polito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Favaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Larosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Marson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Cozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Doria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2018.03.012_bb0005","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0889-857X(03)00016-4","article-title":"Scleroderma renal crisis","volume":"29","author":"Steen","year":"2003","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.autrev.2018.03.012_bb0010","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/00005792-198311000-00001","article-title":"Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases","volume":"62","author":"Traub","year":"1983","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2018.03.012_bb0015","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/543704","article-title":"Scleroderma renal crisis: a pathology perspective","volume":"2010","author":"Batal","year":"2010","journal-title":"Int J Rheumatol"},{"key":"10.1016\/j.autrev.2018.03.012_bb0020","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1002\/art.10589","article-title":"Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose d-penicillamine in early diffuse systemic sclerosis trial","volume":"46","author":"Demarco","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"Suppl 3","key":"10.1016\/j.autrev.2018.03.012_bb0025","first-page":"iii32","article-title":"Renal complications and scleroderma renal crisis","volume":"48","author":"Denton","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2018.03.012_bb0030","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3899\/jrheum.160817","article-title":"Malignancies in patients with anti-RNA polymerase III antibodies and systemic sclerosis: analysis of the EULAR scleroderma trials and research cohort and possible recommendations for screening","volume":"44","author":"Lazzaroni","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2018.03.012_bb0035","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.7326\/0003-4819-119-10-199311150-00007","article-title":"Autoantibody reactive with RNA polymerase III in systemic sclerosis","volume":"119","author":"Okano","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2018.03.012_bb0040","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3109\/03009742.2011.569753","article-title":"Anti-RNA polymerase III antibodies are associated with scleroderma renal crisis in a French cohort","volume":"40","author":"Emilie","year":"2011","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.autrev.2018.03.012_bb0045","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","article-title":"Autoantibodies in systemic sclerosis","volume":"35","author":"Steen","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2018.03.012_bb0050","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/MD.0b013e3181dde28d","article-title":"Systemic sclerosis: establishing diagnostic criteria","volume":"89","author":"Hudson","year":"2010","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2018.03.012_bb0055","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard.2006.062901","article-title":"Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database","volume":"66","author":"Walker","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2018.03.012_bb0060","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.berh.2004.03.001","article-title":"Scleroderma\u2014clinical and pathological advances","volume":"18","author":"Denton","year":"2004","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.autrev.2018.03.012_bb0065","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.autrev.2017.02.012","article-title":"Towards developing criteria for scleroderma renal crisis: a scoping review","volume":"16","author":"Hoa","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.03.012_bb0070","first-page":"S29","article-title":"Assessment of kidney involvement","volume":"21","author":"Steen","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2018.03.012_bb0075","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1136\/ard.2006.066985","article-title":"Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients","volume":"67","author":"Teixeira","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2018.03.012_bb0080","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/anr.1780320911","article-title":"Normotensive renal failure in systemic sclerosis","volume":"32","author":"Helfrich","year":"1989","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2018.03.012_bb0085","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1016\/j.lpm.2014.02.031","article-title":"Kidney involvement in systemic sclerosis","volume":"43","author":"Steen","year":"2014","journal-title":"Presse Med"},{"key":"10.1016\/j.autrev.2018.03.012_bb0090","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.autrev.2017.05.024","article-title":"The role of endothelial cells in the vasculopathy of systemic sclerosis: a systematic review","volume":"16","author":"Mostmans","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.03.012_bb0095","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.humpath.2008.08.001","article-title":"Renal biopsy findings predicting outcome in scleroderma renal crisis","volume":"40","author":"Batal","year":"2009","journal-title":"Hum Pathol"},{"key":"10.1016\/j.autrev.2018.03.012_bb0100","first-page":"29","article-title":"Pathologic observations concerning the kidney in progressive systemic sclerosis","volume":"65","author":"Fischer","year":"1958","journal-title":"AMA Arch Pathol"},{"key":"10.1016\/j.autrev.2018.03.012_bb0105","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/0002-9343(84)90986-0","article-title":"Factors predicting development of renal involvement in progressive systemic sclerosis","volume":"76","author":"Steen","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.autrev.2018.03.012_bb0110","doi-asserted-by":"crossref","first-page":"352","DOI":"10.7326\/0003-4819-113-5-352","article-title":"Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors","volume":"113","author":"Steen","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2018.03.012_bb0115","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1002\/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O","article-title":"Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis","volume":"41","author":"Steen","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2018.03.012_bb0120","first-page":"649","article-title":"Kidney disease other than renal crisis in patients with diffuse scleroderma","volume":"32","author":"Steen","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2018.03.012_bb0125","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.semarthrit.2013.09.008","article-title":"Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the international scleroderma renal crisis survey","volume":"43","author":"Hudson","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2018.03.012_bb0130","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/qjmed\/hcm052","article-title":"Scleroderma renal crisis: patient characteristics and long-term outcomes","volume":"100","author":"Penn","year":"2007","journal-title":"QJM"},{"key":"10.1016\/j.autrev.2018.03.012_bb0135","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1097\/BOR.0b013e3283108df7","article-title":"Diagnosis, management and prevention of scleroderma renal disease","volume":"20","author":"Penn","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2018.03.012_bb0140","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/rheumatology\/ker271","article-title":"Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls","volume":"51","author":"Guillevin","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2018.03.012_bb0145","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2018.03.012_bb0150","first-page":"157","article-title":"Glucocorticoids in systemic sclerosis: weighing the benefits and risks - a systematic review","volume":"31","author":"Iudici","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2018.03.012_bb0155","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/rheumatology\/33.1.90","article-title":"Acute renal failure occurring in scleroderma treated with cyclosporin A: a report of three cases","volume":"33","author":"Denton","year":"1994","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.autrev.2018.03.012_bb0160","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/ki.1985.196","article-title":"Effect of cyclosporine administration on renal hemodynamics in conscious rats","volume":"28","author":"Murray","year":"1985","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2018.03.012_bb0165","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2340\/0001555572307309","article-title":"Hemolytic uremic syndrome in a patient with systemic sclerosis treated with cyclosporin a","volume":"72","author":"Zachariae","year":"1992","journal-title":"Acta Derm Venereol"},{"issue":"Suppl: 33\u20136","key":"10.1016\/j.autrev.2018.03.012_bb0170","article-title":"Incidence and clinical profile of microvascular complications in renal allografted patients treated with cyclosporine","volume":"143","author":"Noel","year":"1992","journal-title":"Ann Med Interne"},{"key":"10.1016\/j.autrev.2018.03.012_bb0175","first-page":"135","article-title":"Effect of dihydropyridine calcium channel blockers and glucocorticoids on the prevention and development of scleroderma renal crisis in an Italian case series","volume":"31","author":"Montanelli","year":"2013","journal-title":"Clin Exp Rheumatol"},{"issue":"122I\u2013127I","key":"10.1016\/j.autrev.2018.03.012_bb0180","article-title":"Effects of amlodipine on renal hemodynamics","volume":"64","author":"Loutzenhiser","year":"1989","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.autrev.2018.03.012_bb0185","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1097\/00005344-200000001-00002","article-title":"Calcium antagonists and renal protection from cyclosporine nephrotoxicity: long-term trial in renal transplantation patients","volume":"35","author":"Rodicio","year":"2000","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.autrev.2018.03.012_bb0190","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.lpm.2007.06.016","article-title":"Iloprost for the treatment of systemic sclerosis","volume":"37","author":"Hachulla","year":"2008","journal-title":"Presse Med"},{"key":"10.1016\/j.autrev.2018.03.012_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-197401000-00001","article-title":"The relationship of hypertension and renal failure in scleroderma (progressive systemic sclerosis) to structural and functional abnormalities of the renal cortical circulation","volume":"53","author":"Cannon","year":"1974","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2018.03.012_bb0200","first-page":"1944","article-title":"Effect of iloprost infusion on the resistance index of renal vessels of patients with systemic sclerosis","volume":"24","author":"Scorza","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2018.03.012_bb0205","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/rheumatology\/40.4.406","article-title":"Renal vascular damage in Japanese patients with systemic sclerosis","volume":"40","author":"Nishijima","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2018.03.012_bb0210","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s00296-011-1878-y","article-title":"Severe vascular complications in patients affected by systemic sclerosis cyclically treated with iloprost","volume":"32","author":"Caramaschi","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2018.03.012_bb0215","first-page":"722","article-title":"Disease-modifying effects of long-term cyclic iloprost therapy in systemic sclerosis. A retrospective analysis and comparison with a control group","volume":"25","author":"Airo","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2018.03.012_bb0220","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1210\/en.2003-0150","article-title":"Minireview: overview of the renin-angiotensin system\u2014an endocrine and paracrine system","volume":"144","author":"Lavoie","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.autrev.2018.03.012_bb0225","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3181\/00379727-150-39039","article-title":"Serum renin and renin substrate levels in scleroderma","volume":"150","author":"Fleischmajer","year":"1975","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.autrev.2018.03.012_bb0230","doi-asserted-by":"crossref","first-page":"P3","DOI":"10.1159\/000066656","article-title":"The renin-angiotensin system and progression of renal disease: from hemodynamics to cell biology","volume":"93","author":"Wolf","year":"2003","journal-title":"Nephron Physiol"},{"key":"10.1016\/j.autrev.2018.03.012_bb0235","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/sj.ki.5000260","article-title":"Perspectives on blockade of TGFbeta overexpression","volume":"69","author":"Huang","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2018.03.012_bb0240","doi-asserted-by":"crossref","first-page":"900","DOI":"10.5301\/jn.5000134","article-title":"Renin-angiotensin-aldosterone system blockade for nephroprotection: current evidence and future directions","volume":"25","author":"Tylicki","year":"2012","journal-title":"J Nephrol"},{"key":"10.1016\/j.autrev.2018.03.012_bb0245","doi-asserted-by":"crossref","first-page":"600","DOI":"10.7326\/0003-4819-133-8-200010170-00010","article-title":"Long-term outcomes of scleroderma renal crisis","volume":"133","author":"Steen","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2018.03.012_bb0250","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/BOR.0b013e3283588dcf","article-title":"Renal disease in scleroderma: an update on evaluation, risk stratification, pathogenesis and management","volume":"24","author":"Shanmugam","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2018.03.012_bb0255","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nrneph.2017.183","article-title":"Scleroderma renal crisis and renal involvement in systemic sclerosis","volume":"14","author":"Woodworth","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.autrev.2018.03.012_bb0260","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1093\/ndt\/gfq861","article-title":"End-stage kidney disease due to scleroderma\u2014outcomes in 127 consecutive ANZDATA registry cases","volume":"26","author":"Siva","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2018.03.012_bb0265","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0140-6736(05)61568-1","article-title":"Failure of losartan to control blood pressure in scleroderma renal crisis","volume":"349","author":"Caskey","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2018.03.012_bb0270","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1053\/j.ajkd.2005.01.007","article-title":"Late recurrence of scleroderma renal crisis in a renal transplant recipient despite angiotensin II blockade","volume":"45","author":"Cheung","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.autrev.2018.03.012_bb0275","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2018.03.012_bb0280","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1053\/j.ajkd.2009.02.015","article-title":"Endothelin receptor antagonism and renin inhibition as treatment options for scleroderma kidney","volume":"54","author":"Dhaun","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.autrev.2018.03.012_bb0285","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/S0140-6736(01)06298-5","article-title":"Endothelin-receptor antagonists in pulmonary hypertension","volume":"358","author":"Dupuis","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2018.03.012_bb0290","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/ki.2013.157","article-title":"Progressive endothelin-1 gene activation initiates chronic\/end-stage renal disease following experimental ischemic\/reperfusion injury","volume":"84","author":"Zager","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2018.03.012_bb0295","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/0022-2828(90)90115-I","article-title":"Endothelin stimulates angiotensin I to angiotensin II conversion in cultured pulmonary artery endothelial cells","volume":"22","author":"Kawaguchi","year":"1990","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.autrev.2018.03.012_bb0300","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/ckj\/sfs001","article-title":"Endothelin and the podocyte","volume":"5","author":"Barton","year":"2012","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.autrev.2018.03.012_bb0305","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/qjmed\/hct111","article-title":"Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility","volume":"106","author":"Penn","year":"2013","journal-title":"QJM"},{"key":"10.1016\/j.autrev.2018.03.012_bb0310","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.humpath.2010.05.018","article-title":"Endothelin-1 expression in scleroderma renal crisis","volume":"42","author":"Mouthon","year":"2011","journal-title":"Hum Pathol"},{"key":"10.1016\/j.autrev.2018.03.012_bb0315","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1681\/ASN.2008050482","article-title":"Avosentan reduces albumin excretion in diabetics with macroalbuminuria","volume":"20","author":"Wenzel","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2018.03.012_bb0320","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1681\/ASN.2009060593","article-title":"Avosentan for overt diabetic nephropathy","volume":"21","author":"Mann","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2018.03.012_bb0325","first-page":"61","article-title":"Bosentan in pulmonary arterial hypertension secondary to scleroderma","volume":"33","author":"Joglekar","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2018.03.012_bb0330","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.autrev.2017.11.020","article-title":"Scleroderma skin ulcers definition, classification and treatment strategies our experience and review of the literature","volume":"17","author":"Giuggioli","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.03.012_bb0335","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s10067-013-2172-z","article-title":"Low occurrence of digital ulcers in scleroderma patients treated with bosentan for pulmonary arterial hypertension: a retrospective case-control study","volume":"32","author":"Cozzi","year":"2013","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2018.03.012_bb0340","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1053\/j.ajkd.2013.04.016","article-title":"Endothelin receptor antagonism-based treatment for scleroderma renal crisis","volume":"62","author":"Izzedine","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.autrev.2018.03.012_bb0345","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/ki.2014.143","article-title":"Endothelin and endothelin antagonists in chronic kidney disease","volume":"86","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2018.03.012_bb0350","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1556\/EuJMI.2.2012.2.2","article-title":"The complement system: history, pathways, cascade and inhibitors","volume":"2","author":"Nesargikar","year":"2012","journal-title":"Eur J Microbiol Immunol (Bp)"},{"key":"10.1016\/j.autrev.2018.03.012_bb0355","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1177\/0961203307083279","article-title":"Peritubular capillary C4d deposition in lupus nephritis different from antibody-mediated renal rejection","volume":"16","author":"Li","year":"2007","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2018.03.012_bb0360","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1365-2249.1991.tb02954.x","article-title":"Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection","volume":"86","author":"Feucht","year":"1991","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2018.03.012_bb0365","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/anr.1780321011","article-title":"Activation of the complement system in systemic sclerosis. Relationship to clinical severity","volume":"32","author":"Senaldi","year":"1989","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2018.03.012_bb0370","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/MD.0000000000004459","article-title":"Complement activation and effect of eculizumab in scleroderma renal crisis","volume":"95","author":"Devresse","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2018.03.012_bb0375","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s13075-016-1168-x","article-title":"Analysis of complement biomarkers in systemic sclerosis indicates a distinct pattern in scleroderma renal crisis","volume":"18","author":"Okroj","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2018.03.012_bb0380","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2018.03.012_bb0385","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/ckj\/sfv101","article-title":"Eculizumab for rescue of thrombotic microangiopathy in PM-Scl antibody-positive autoimmune overlap syndrome","volume":"8","author":"Thomas","year":"2015","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.autrev.2018.03.012_bb0390","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.thromres.2007.11.005","article-title":"Regulated complement deposition on the surface of human endothelial cells: effect of tobacco smoke and shear stress","volume":"122","author":"Yin","year":"2008","journal-title":"Thromb Res"},{"key":"10.1016\/j.autrev.2018.03.012_bb0395","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/1529-0131(200004)43:4<889::AID-ANR21>3.0.CO;2-5","article-title":"Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis","volume":"43","author":"Hebbar","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2018.03.012_bb0400","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/00002281-199811000-00011","article-title":"Biology of the scleroderma fibroblast","volume":"10","author":"Strehlow","year":"1998","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2018.03.012_bb0405","first-page":"149","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American society for apheresis: the seventh special issue","volume":"31","author":"Schwartz","year":"2016","journal-title":"J Clin Apher"},{"key":"10.1016\/j.autrev.2018.03.012_bb0410","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00467-007-0452-z","article-title":"The role of angiotensin II type 1 receptor-activating antibodies in renal allograft vascular rejection","volume":"22","author":"Dragun","year":"2007","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.autrev.2018.03.012_bb0415","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1473-0502(01)00078-7","article-title":"Long-term therapy with plasma exchange in systemic sclerosis: effects on laboratory markers reflecting disease activity","volume":"25","author":"Cozzi","year":"2001","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.autrev.2018.03.012_bb0420","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1093\/ndt\/gfs317","article-title":"Prognosis of scleroderma renal crisis: a long-term observational study","volume":"27","author":"Cozzi","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2018.03.012_bb0425","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.transci.2006.05.014","article-title":"Therapeutic plasma exchange for the treatment of thrombotic thrombocytopenic purpura: a retrospective multicenter study","volume":"36","author":"Altuntas","year":"2007","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.autrev.2018.03.012_bb0430","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1182\/asheducation-2017.1.632","article-title":"Plasma exchange in thrombotic microangiopathies (TMAs) other than thrombotic thrombocytopenic purpura (TTP)","volume":"2017","author":"Winters","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.autrev.2018.03.012_bb0435","doi-asserted-by":"crossref","first-page":"116","DOI":"10.2177\/jsci.38.116","article-title":"13-year history of scleroderma complicated by renal crisis and thrombotic microangiopathy treated with plasma exchange: a case report","volume":"38","author":"Minami","year":"2015","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"key":"10.1016\/j.autrev.2018.03.012_bb0440","first-page":"329","article-title":"Scleroderma renal crisis during intravenous cyclophosphamide pulse therapy for complicated interstitial lung disease was successfully treated with angiotensin converting enzyme inhibitor and plasma exchange","volume":"78","author":"Nagamura","year":"2016","journal-title":"Nagoya J Med Sci"},{"key":"10.1016\/j.autrev.2018.03.012_bb0445","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/00005792-199911000-00003","article-title":"Renal transplantation in scleroderma","volume":"78","author":"Chang","year":"1999","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2018.03.012_bb0450","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1111\/j.1600-6143.2005.01035.x","article-title":"Predictors and risk factors for recurrent scleroderma renal crisis in the kidney allograft: case report and review of the literature","volume":"5","author":"Pham","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.autrev.2018.03.012_bb0455","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/tri.12923","article-title":"Kidney transplantation in patients with systemic sclerosis: a nationwide multicentre study","volume":"30","author":"Bertrand","year":"2017","journal-title":"Transpl Int"},{"key":"10.1016\/j.autrev.2018.03.012_bb0460","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1046\/j.1445-5994.2003.00358.x","article-title":"Scleroderma renal crisis: poor outcome despite aggressive antihypertensive treatment","volume":"33","author":"Walker","year":"2003","journal-title":"Intern Med J"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997218301575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997218301575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T12:58:47Z","timestamp":1693745927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997218301575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":92,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1568997218301575"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2018.03.012","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapy of scleroderma renal crisis: State of the art","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2018.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}